Á lódáil...
Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma (HCC) in de-differentiation stage (presenting epithelial–mesenchymal transition, EMT). We studied the role of the thioredoxin system (Trx1/TrxR1) in the sensitivity or resistance of HCC cells to the treatment...
Na minha lista:
| Foilsithe in: | Antioxidants (Basel) |
|---|---|
| Main Authors: | , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
MDPI
2019
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6826379/ https://ncbi.nlm.nih.gov/pubmed/31652503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antiox8100501 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|